T
Tomaz B. Manzoni
Researcher at University of Pennsylvania
Publications - 12
Citations - 1209
Tomaz B. Manzoni is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Virus & Coronavirus. The author has an hindex of 8, co-authored 10 publications receiving 451 citations.
Papers
More filters
Journal ArticleDOI
Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection.
Elizabeth M. Anderson,Eileen C. Goodwin,Anurag Verma,Claudia P. Arevalo,Marcus J. Bolton,Madison E. Weirick,Sigrid Gouma,Christopher M McAllister,Shannon R. Christensen,JoEllen Weaver,Philip Hicks,Tomaz B. Manzoni,Oluwatosin Oniyide,Holly Ramage,Divij Mathew,Amy E. Baxter,Derek A. Oldridge,Allison R. Greenplate,Jennifer E. Wu,Cécile Alanio,Kurt D'Andrea,Oliva Kuthuru,Jeanette Dougherty,Ajinkya Pattekar,Justin Kim,Nicholas Han,Sokratis A. Apostolidis,Alexander C. Huang,Laura A. Vella,Laura A. Vella,Leticia Kuri-Cervantes,M. Betina Pampena,Michael R. Betts,E. John Wherry,Nuala J. Meyer,Sara Cherry,Paul Bates,Daniel J. Rader,Scott E. Hensley +38 more
TL;DR: In this paper, the authors quantified levels of SARS-CoV-2-reactive antibodies and hCoVreactive antibody in serum samples collected from 431 individuals before the COVID-19 pandemic, and then quantified pre-pandemic antibody levels in serum from a separate cohort of 251 individuals who became PCR-confirmed infected with SARS CoV 2.
Journal ArticleDOI
SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation.
Katlyn Lederer,Diana Castaño,Diana Castaño,Daniela Gómez Atria,Thomas H. Oguin,Sidney Wang,Tomaz B. Manzoni,Hiromi Muramatsu,Michael J. Hogan,Fatima Amanat,Patrick Cherubin,Kendall A. Lundgreen,Ying K. Tam,Steven H.Y. Fan,Laurence C. Eisenlohr,Laurence C. Eisenlohr,Ivan Maillard,Drew Weissman,Paul Bates,Florian Krammer,Gregory D. Sempowski,Norbert Pardi,Michela Locci +22 more
TL;DR: Overall, this study identifies SARS-CoV-2 mRNA vaccines as strong candidates for promoting robust GC-derived immune responses and directly compared two vaccine platforms −mRNA vaccines and a recombinant protein formulated with an MF59-like adjuvant− for their ability to quantitatively and qualitatively shape Sars-Cov-2-specific primary GC responses over time.
Journal ArticleDOI
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice.
Dorottya Laczkó,Michael J. Hogan,Sushila A. Toulmin,Philip Hicks,Katlyn Lederer,Brian T. Gaudette,Diana Castaño,Diana Castaño,Fatima Amanat,Hiromi Muramatsu,Thomas H. Oguin,Amrita Ojha,Lizhou Zhang,Zekun Mu,Robert Parks,Tomaz B. Manzoni,Brianne Roper,Shirin Strohmeier,István Tombácz,Leslee Arwood,Raffael Nachbagauer,Katalin Karikó,Jack Greenhouse,Laurent Pessaint,Maciel Porto,Tammy Putman-Taylor,Amanda Strasbaugh,Tracey Ann Campbell,Paulo J.C. Lin,Ying K. Tam,Gregory D. Sempowski,Michael Farzan,Hyeryun Choe,Kevin O. Saunders,Barton F. Haynes,Hanne Leth Andersen,Laurence C. Eisenlohr,Laurence C. Eisenlohr,Drew Weissman,Florian Krammer,Paul Bates,David Allman,Michela Locci,Norbert Pardi +43 more
TL;DR: It is suggested that the nucleoside-modified mRNA-LNP vaccine platform can induce robust immune responses and is a promising candidate to combat COVID-19.
Journal ArticleDOI
Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses
Mohamad-Gabriel Alameh,István Tombácz,Emily Bettini,Katlyn Lederer,Chutamath Sittplangkoon,Joel R. Wilmore,Brian T. Gaudette,Ousamah Younoss Soliman,Matthew Pine,Philip Hicks,Tomaz B. Manzoni,James J. Knox,John L. Johnson,Dorottya Laczkó,Hiromi Muramatsu,Benjamin Davis,Wenzhao Meng,Aaron M. Rosenfeld,Shirin Strohmeier,Paulo J.C. Lin,Barbara L. Mui,Ying K. Tam,Katalin Karikó,Alain Jacquet,Florian Krammer,Paul Bates,Michael P. Cancro,Drew Weissman,Eline T. Luning Prak,David Allman,Michela Locci,Norbert Pardi +31 more
TL;DR: In this article, a lipid nanoparticle (LNP)-encapsulated nucleoside-modified mRNA vaccines have shown great efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but the mechanism of action of this vaccine platform is not well-characterized.
Posted ContentDOI
Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection
Elizabeth M. Anderson,Eileen C. Goodwin,Anurag Verma,Claudia P. Arevalo,Marcus J. Bolton,Madison E. Weirick,Sigrid Gouma,Christopher M McAllister,Shannon R. Christensen,JoEllen Weaver,Phillip Hicks,Tomaz B. Manzoni,Oluwatosin Oniyide,Holly Ramage,Holly Ramage,Divij Mathew,Amy E. Baxter,Derek A. Oldridge,Allison R. Greenplate,Jennifer E. Wu,Cécile Alanio,Kurt D'Andrea,Oliva Kuthuru,Jeanette Dougherty,Ajinkya Pattekar,Justin Kim,Nicholas Han,Sokratis A. Apostolidis,Alexander C. Huang,Laura A. Vella,Laura A. Vella,E. John Wherry,Nuala J. Meyer,Sara Cherry,Paul Bates,Daniel J. Rader,Scott E. Hensley +36 more
TL;DR: These studies indicate that most individuals possessed hCoV-reactive antibodies before the COVID-19 pandemic, and that ~23% of these individuals possessed non-neutralizing antibodies that cross-reacted with SARS- CoV-2 spike and nucleocapsid proteins.